Navigation Links
OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China

HONG KONG, Feb. 11 /PRNewswire/ -- OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China.

A multicenter, randomized, controlled study, the trial will enroll 180 patients split evenly between the control and test arms at 11 sites countrywide. The primary study objective is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor Sprint stent.  

The study population will consist of patients ages 18 to 75 with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months following implant and 270 day angiographic Late Loss (LL). Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.  

The first patient was enrolled in the study at Beijing Chaoyang Hospital on December 8, 2009.

"We believe that the Genous Bio-engineered R stent will provide an excellent treatment option to patients who present challenging cases with standard drug eluting stents," said Prof. Lu Shuzheng from Anzhen Hospital, principal investigator of the trial.

Al Novak, OrbusNeich's chairman and CEO, added, "We are excited to take the Genous Bio-engineered R stent into this pivotal trial in China. We expect that clinical data from this study will show positive benefits for patients, including those who often encounter challenges with today's drug eluting stents."

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005.  The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies.  There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, SafeCut™, Sapphire™, Sapphire NC, Avita™, Avita HP and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China.  OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit  

SOURCE OrbusNeich



SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
(Date:10/12/2015)... 2015 Contrast media injectors ... the quality of images produced inside of the ... used in magnetic resonance imaging, medical X-ray, computed ... the radiologists to interpret the images accurately and ... body. Contrast media can be administered by three ...
(Date:10/12/2015)... , Oct. 12, 2015 Leadership of the National ... familiar face as Aspasia Shappet , CEO of MESVision ... from the NAVCP Board at its annual strategic planning meeting ... served as Chairwoman of the organization from May 2013 to ... who stepped down as a result of the increased demands ...
(Date:10/12/2015)... 12, 2015 --> ... Market by Product (Hand-held, Table-top, Desktop), Technology (Volume Measurement, Flow ... Geography - Global Forecast to 2020", published by MarketsandMarkets, the ... 2020, at a CAGR of 9.8% from 2015 to 2020. ... igures spread th rough 187 P ages ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... Georgia Partnership for TeleHealth (GPT), ... along with affiliate organizations, Alabama Partnership for Telehalth (ATP) and Florida Partnership for ... 2015. , Each of the three conferences share this year’s conference theme, ...
(Date:10/13/2015)... Cheyenne, Wyoming (PRWEB) , ... October 13, 2015 , ... ... at the Gold’s Gym International Conference on August 26. Berry, who owns and operates ... exemplary standards for the fastest growing Gold’s Gyms in the United States. A brand ...
(Date:10/13/2015)... ... ... With Fall weather approaching and holiday travel season upon us, is giving ... Enter to win! , How to Enter:, 1. Like on Facebook , ... Follow us on Instagram @thebeautyplace , 4. Share Facebook Contest Image With Friends ...
(Date:10/13/2015)... ... October 13, 2015 , ... Bambeco, ... furnishings and décor, today announced it closed on a $20.5 million funding round ... be used to support the Company’s continued rapid growth and expansion, broaden the ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... National Women’s show this coming October in Toronto, an exhibition featuring the newest ... to choose from, Curly Hair Solutions® couldn’t be more excited to unveil their ...
Breaking Medicine News(10 mins):